Table 4.

Risk classification for first postoperative biomarkers after addition to clinical model for severe AKI

Clinical Model, Frequency (Row Percent)Clinical Model + BiomarkerTotal
<10%10 to 25%>25%
Urine IL-18
    AKI participants
        <10%2 (50.0%)2 (50.0%)0 (0%)4
        10 to 25%2 (8.7%)7 (30.4%)14 (60.9%)23
        >25%0 (0%)4 (16.0%)21 (84.0%)25
        Total4133552
    Non-AKI participants
        <10%107 (88.4%)14 (11.6%)0 (0%)121
        10 to 25%34 (34.3%)47 (47.5%)18 (18.2%)99
        >25%0 (0%)7 (21.2%)26 (78.8%)33
        Total1416844253
Urine NGAL
    AKI participants
        <10%2 (50.0%)2 (50.0%)0 (0%)4
        10 to 25%0 (0%)14 (60.9%)9 (39.1%)23
        >25%0 (0%)3 (12.0%)22 (88%)25
        Total2193152
    Non-AKI participants
        <10%114 (94.2%)7 (5.8%)0 (0%)121
        10 to 25%18 (18.2%)70 (70.7%)11 (11.1%)99
        >25%0 (0%)6 (18.2%)27 (81.8%)33
        Total1328338253
Plasma NGAL
    AKI participants
        <10%3 (100%)0 (0%)0 (0%)3
        10 to 25%0 (0%)15 (68.2%)7 (31.8%)22
        >25%0 (0%)1 (4.2%)23 (95.8%)24
        Total3163049
    Non-AKI participants
        <10%102 (91.1%)10 (8.9%)0 (0%)112
        10 to 25%23 (24.7%)59 (63.4%)11 (11.8%)93
        >25%0 (0%)5 (16.7%)25 (83.3%)30
        Total1257436235
  • Clinical model is: age (per year), gender, Caucasian race, nonelective surgery, CPB time ≥120 min, RACHS ≥3, eGFR percentile, and site. Severe AKI is defined as the receipt of dialysis or a doubling of serum creatinine during hospitalization.